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Diarrheal diseases are a major cause of morbidity and mortality worldwide. They are most
prevalent in settings with inadequate sanitation, poor hygiene and contaminated water.
An important diarrheal pathogen in such settings is Shigella. No commercially available
vaccine exists against shigellosis and immunity to the pathogen is serotype-restricted.
We have previously shown that a polypeptide fusion of the Type Three Secretion
Apparatus (T3SA) proteins IpaB and IpaD (named DBF) was efficacious as a
vaccine against Shigella. Vaccination using different administration routes indicated
that protection conferred by DBF did not fully correlate with antibodies. To define the
immune responses involved in protection, we studied cellular responses to intranasal
immunization with the DBF and the adjuvant dmLT. We found dendritic cell (DC) activation
at the nasal associated lymphoid tissue (NALT). Activation markers CD86 and MHCII
significantly increase in cells from immunized mice. Antigen exposure in vitro further
confirmed the upregulation of CD80 and CD40 in primary dendritic cells. Animals
immunized with antigen-primed dendritic cells were protected against Shigella infection,
at levels comparable to the efficacy of immunization with the protein vaccine formulation.
Therefore, we show that antigen-primed DCs are enough to provide immunity, and
propose amechanism of protection against Shigella spp. based on DC-mediated antigen
presentation to T cells.
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INTRODUCTION
Shigellosis poses a significant public health burden, especially in developing countries. The most
recent analysis of samples from Africa and Asia indicates Shigella spp. are a leading cause of
diarrheal events in children under the age of 5 (1). Diarrheal disease caused by Shigella spp. and
enterotoxigenic Escherichia coli (ETEC) account for more than 75,000 deaths in this age group
each year (2). In older children and adults from the same region, Shigella spp. cause almost 90
million cases and 5 million hospitalizations each year (3). Improved sanitation and safe water
supplies can reduce morbidity and mortality due to diarrhea; however, in impoverished settings
these improvements are lacking due to poor infrastructure, high population density and low
governmental involvement (4, 5). To overcome these challenges, the development of vaccines
is necessary.
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For Shigella, efforts to generate a commercially available
vaccine are hindered by the presence of more than 50 serotypes
of four different species (S. flexneri, S. sonnei, S. dysenteriae,
and S. boydii). Subunit vaccines targeting conserved proteins
can address this barrier by providing heterologous protection
across multiple species/serotypes (6). Our group has developed
a subunit vaccine based on the Type III Secretion System
(T3SS) proteins of Shigella called IpaB and IpaD, which are well
conserved across all species and serotypes. This subunit vaccine
has been extensively tested in combination with the adjuvant
dmLT, a double-mutant of the heat labile toxin of ETEC, as well
as with other adjuvants (7–9).
The vaccine was further optimized with development of the
chimeric protein DBF, which protects mice against pulmonary
challenge with S. flexneri, S. sonnei and S. dysenteriae (10, 11).
DBF is able to elicit comparable titers of protein-specific IgG
and IgA antibodies to those of the combination formulation
IpaB+IpaD. However, certain markers of Th1/Th17 polarization
are further elevated in the spleen when DBF is used for
immunization. These markers include the presence of IFN-γ
secreting cells, increased secretion of IL-17A and decreased
secretion of IL-4 in splenocytes in response to antigens in vitro
(10). While protective efficacy against challenge with S. flexneri
and S. sonnei were comparable between both versions of the
vaccine, only DBF provided protection against S. dysenteriae,
the toxin-producing Shigella spp. that causes severe dysentery
and hemolytic uremic syndrome. Furthermore, a second study
that compared different vehicle preparations with DBF+dmLT
showed a better protective efficacy with Lauryldimethylamine
N-oxide (LDAO) relative to the n-Octyl-oligo-oxyethylene
(OPOE)-containing vehicle (11). Immunization with either
elicited almost identical IgG titers but significantly higher
splenocyte secretion of IL-17A was observed in the LDAO
formulated protein, which highlights the potential role of cell
mediated immunity for protection.
In this study, we further dissect the role of cellular
immunity in the antigenicity and protective efficacy of DBF
and its combined formulation with dmLT. Protective immunity
conferred by dendritic cells (DCs), T-cells and B-cells is
recognized as a hallmark of both resolution of natural infection
and vaccination. In the case of Shigella spp. bacterium-specific
cell mediated responses are primarily due to the generation of
Th1/Th17 CD4+ cells (12, 13). Whereas, primary infection with
S. flexneri induces differentiation of CD4+ cells to Th17 cells that
produce IL-17A and IL-22, secondary infection also produces
Th1 cells that secrete IFN-γ. CD4+ cell stimulation assays did not
detect IL-4, denoting a lack of polarization toward Th2 lineage.
Priming of Th17 cells was via MHCII and IL-6 cues by antigen
presenting cells (13).
Immunization can also mimic these primary responses
present during infection. For example, it has previously been
shown that an attenuated Shigella dysenteriae strain used as a
vaccine elicited Th1/Th17 responses (14). Macrophages from
immunized animals secrete significantly higher amounts of IL-6,
IL-23, IL-12p70, and IL-1β, which in the context of antigen-
presenting cells would create a polarization environment of
CD4+ cells toward the Th1/Th17 lineages. Indeed, CD4+ cells
isolated from spleens of immunized animals secrete higher levels
of the canonical Th1 cytokine IFN-γ and Th17 cytokine IL-17A
relative to controls. Modulatory cytokine IL-10 was also elevated,
whereas Th2 cytokine IL-4 had no significant change between
groups (14).
Therefore, we analyzed the responses at the site of
immunization by antigen-primed DCs and T cells, as well as the
profiles prompted by their interaction in a simplified in vitro
model. Adoptive transfer was also used as an immunization
trial, in which DCs delivered intranasally were able to confer
protection against pulmonary challenge. The immune response
elicited by this vaccination included the generation of memory
T cells with a distinctive lack of antibody responses against
the Shigella antigens. Our findings support the hypothesis
that cell-mediated immunity elicited by DCs plays a crucial
role for protection against Shigella spp. conferred by the
DBF+dmLT vaccine.
RESULTS
Intranasal Immunization With DBF+dmLT
Triggers Activation of Dendritic Cells
Mice were immunized intranasally with vaccine formulations
of DBF either alone or adjuvanted with dmLT, or dmLT
alone. A control group was administered PBS. After 6 h,
the dendritic cell (DC) population found in the NALT was
analyzed by flow cytometry (Figure 1). The percentage of
CD11c+ cells remained unchanged across all groups (Figure 1A,
right), however, their activation profile was altered as indicated
by the levels of MHCII, CD86, and CD80. Immunization
with DBF+dmLT produces significantly different activated
DC populations to those elicited by DBF or dmLT alone.
The median fluorescence intensity (MFI) values show an
increase in MHCII and CD86 but not CD80, which showed
a reduction in MFI in this group (Figure 1B). A marked
increase is evident for levels of both MHCII and CD86 across
treatments, with the highest levels observed for DBF+dmLT
(Figure 1B, left and middle panels). These trends are not
observed for CD80, as a reduction is observed in all groups
(including DBF+dmLT) compared to PBS control (Figure 1B,
right panel). Differential changes in levels of these activation
markers point to the presence of different DC activation
states depending upon the treatment. This is evidenced by
a significant increase in the population positive for MHCII,
CD86, or both in the group immunized with DBF+dmLT
when compared to the PBS group (Figure 1C, top panels). An
increase in the CD80+ and CD80/CD86+ populations in the
group immunized with either dmLT or DBF+dmLT is apparent
but not significant (Figure 1C, bottom panels). There are no
significant increases for any of the measured markers in the
groups immunized with the protein or adjuvant alone, suggesting
that both components of the vaccine are needed to activate
these cells.
NALT samples were also analyzed for differences in the
number of T cells (Figure S1A) and macrophages (Figure S1B)
and no significant differences were found across groups for
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FIGURE 1 | Dendritic cell populations in NALT post-immunization. Nasal-associated lymphoid tissue (NALT) was harvested from BALB/c mice 6 h after immunization
with PBS, DBF, dmLT, and the combination DBF+dmLT. Cells in NALT were isolated and stained as described in Materials and Methods. (A) Dendritic cells were
recognized by positive CD11c labeling (left). The percentage of CD11c+ cells was measured in NALT (right). (B) Expression of MHCII, CD86, and CD80 from a
representative sample for each treatment. Fluorescence minus one (FMO) controls are shown for comparison. Numbers present inside the grids indicate median
fluorescence intensity (MFI). (C) CD11c+ populations show differential percentages MHCII, CD86, and MHCII CD86 double positive cells. Each point represents a
different individual. Error bars indicate standard deviation. Statistical significance was analyzed with an ordinary one-way ANOVA with a Tukey post-hoc test. All
comparisons tested with an α value of 0.05. *p < 0.05 vs. PBS, #p < 0.05 vs. DBF.
either population. The activation state of each population was
also measured as percent positive for CD69 in CD3+ cells
or percent positive for MHCII in F4/80+ cells. No significant
differences were found in the activation state of these populations
across groups.
Primary DC Stimulation Causes Activation
Marker Upregulation
To further define the activation state of DCs in response to these
proteins, we measured the activation of primary cells in direct
stimulation assays. Bone marrow derived DCs were stimulated
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FIGURE 2 | Antigen exposure promotes activation of bone-marrow derived DCs. Mouse bone marrow cells were differentiated into CD11c+ cells by 8-day culture in
the presence of GM-CSF as described in Materials and Methods. (A) DC populations exposed to PBS, DBF, dmLT, and the combination DBF+dmLT were analyzed
for expression of activation markers MHCII, CD86, CD80, and CD40 by flow cytometry. Stacked histograms show the fluorescence distribution and MFI values for
each marker in a representative sample of each treatment. Some treatments induce a bi- or trimodal distribution of marker fluorescence. Fluorescence minus one
(FMO) controls are shown for comparison. (B) Differences in positive populations for each marker were assessed by setting a cut-off of negative fluorescence with
FMO samples. Percent positive populations for MHCII, CD86, CD40, and CD80 are shown using that criterion. Additionally, trimodal distributions for MCHII and CD86
allowed for an alternative histogram gate for distinct populations MHCIIhi and CD86hi. Their differences across treatments are also shown. (C) Percentages of the total
DC population were analyzed for co-expression of CD80 and CD86 (top graph). The gated population double positive for CD80 and CD86 was further analyzed for
co-expression of CD40 and MHCII (bottom graph). (D) Contour plots for CD80+ CD86+ populations further represent the differences in their distribution of MCHII+,
CD40+, and MHCII+ CD40+ cells. Each bar represents the mean and SEM of duplicate biological samples. Statistical significance was analyzed with an ordinary
one-way ANOVA with a Tukey post-hoc test. All comparisons tested with an α value of 0.05. *p < 0.05, **p < 0.01, ***p < 0.001.
in vitro for 48 h with DBF, dmLT, or the combination. A control
group remained unstimulated by culture with PBS (Figure 2).
Analysis of MFI values shows that treatment with DBF, dmLT,
or the combination increase the levels of MHCII and CD86 in
these cells (Figure 2A, left two panels). In vitro, the levels of
CD80 increased in all groups that received dmLT with or without
DBF (Figure 2A, third panel). The levels of CD40 incremented
sharply in cells stimulated with DBF, while dmLT treated cells
(alone or in combination) showed an intermediate increase
(Figure 2A, right panel). When these cells are analyzed for the
frequency of positive cells, significant increases in the MHC+
population were observed for cells stimulated with DBF and
DBF+dmLT vs. control (Figure 2B, top left). When examined
for CD86, all stimulated groups were significantly higher than
the control (Figure 2B, center left). Interestingly, the histogram
profiles showed a third population with distinctly higher levels
of MHCII or CD86 for all samples. Stimulation with DBF led
to higher frequencies of these MCHIIhi or CD86hi populations,
while stimulation with dmLT (alone or in combination) increased
the intermediate population of these markers (Figure 2B, top
and center right). CD40 is only significantly increased in cells
stimulated with DBF, while the presence of dmLT drives surface
expression of CD80 in these cells (Figure 2B, bottom left and
right, respectively).
When the combination of markers is analyzed, we detect a
significant increase in the CD80+ CD86+ population in cells
stimulated dmLT or with DBF +dmLT, while cells stimulated
with DBF alone do not have increased percentages of this
double positive population (Figure 2C, top). Analysis of the
levels of CD40 and MHCII in the population positive for
CD80 and CD86 shows that treatment influences the generation
of cell populations positive for all four analyzed markers.
Interestingly, the majority of CD80+ CD86+ cells in the
dmLT treated groups are not CD40+ MHCII+ (quadruple
positive), while the smaller population of CD80+ CD86+
cells in the DBF treatment are (Figure 2C, bottom). This
is indicated in the density plots for MHCII vs. CD40 in
the CD80+ CD86+ population, where a distinct higher
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FIGURE 3 | Differences in CD86lo and CD86hi DC populations. (A) DC populations exposed to PBS, DBF, dmLT and the combination DBF+dmLT show a trimodal
distribution of CD86. Differences in the abundance of the CD86hi population are evident across treatments, with an enrichment in antigen-treated DCs. Numbers
provided are percentages of total population. (B) Distribution analysis of the CD86+ DC population. (C) Comparison between CD86lo and CD86hi populations for
activation markers CD80, MHCIIhi and CD40. CD80 is differentially distributed between the two populations, whereas all MHCIIhi and CD40+ cells were also CD86hi.
Each bar represents the mean and SEM of duplicate biological samples. Statistical significance was analyzed with a 2-way ANOVA with a Sidak post-hoc test. All
comparisons tested with an α value of 0.05. *p < 0.05, **p < 0.01, ***p < 0.001.
frequency of MHCII+ cells is observed in DBF treated cells
irrespective of CD40, while cells treated with DBF+dmLT
have lower frequencies of MHCII positive cells (91.8 vs.
61.6%, Figure 2D, upper right). Again, the presence of three
distinct populations for MHCII is evident in the DBF+dmLT
group, even if the population is gated on CD80/CD86 double
positives (Figure 2D).
For all markers, it is evident that DBF and dmLT do not
act additively in the upregulation of DC activation signals. This
indicates a unique interplay between DBF and dmLT in their
activation effects. Furthermore, responses to DBF+dmLT were
less pronounced than those for DBF on all markers except CD86.
Distinct CD86 Populations Show
Differences in Other Activation Signals
Population plots show marked distribution patterns of treated
bone marrow-derived DCs with three CD86 surface levels: no
increase, low (CD86lo) and high (CD86hi) surface expression
(Figure 3A). These density plots provide further evidence
that DBF provokes a radical shift toward elevated CD86
expression. A stacked graph illustrates that even though cells
treated with all three protein combinations have comparable
CD86+ percentages, high expression is more prevalent in
the DBF treated sample (Figure 3B). Interestingly, when the
other cell markers are analyzed based on CD86 distribution,
CD80 is differentially distributed between CD86 levels
depending on treatment, with dmLT again eliciting discreet
cell surface marker upregulation with a significantly higher
CD80+ population in those with moderate CD86 (CD86lo
population) (Figure 3C). Treatment with DBF+dmLT yields
the presence of CD80+ population evenly divided in CD86hi
and CD86lo populations. For all samples treated with proteins,
MCHIIhi and CD40+ populations are exclusively found in the
CD86hi category.
Specific Patterns of T Cell Polarizing
Cytokines Are Induced by DC-Mediated
Activation
To investigate whether the differences in the patterns of
activation markers in dendritic cells could differentially influence
polarization of Th cells, well-defined cytokines were measured in
the supernatants of stimulated bone marrow-derived dendritic
cell (BMDC) cultures (Figure 4). High expression levels of IL-6,
a cytokine critical for Th17 polarization, was observed in samples
stimulated with all proteins tested, while PBS controls showed
negligible amounts of this cytokine (Figure 4A). Conversely,
highly variable in levels of the Th1 polarization cytokine IL-12p70
were found across groups but no significant differences were
found among treatments (Figure 4B). The Th2 polarization
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cytokine IL-4 was found only in stimulated samples, similar
to the effect seen for IL-6, although at much lower levels
(Figure 4C). In the case of modulatory responses, cumulative
increases were measured for IL-10 for DBF, adjuvant and
then the combination, with significant differences across all
treatments (Figure 4D).
Stimulation of DCs Causes Different
Proliferation and Cytokine Patterns in T
Helper Cells
To test for the actual polarization effect of stimulated DCs
on T cells, splenocytes from mice previously immunized
intranasally with DBF+dmLT were obtained and the CD4+
population isolated. These cells were subsequently incubated
with BMDCs previously treated with DBF, dmLT, and the
combination. These activated Th cells showed differential
patterns of proliferation depending on the treatment of
the DCs stimulating them (Figure 5A). All protein treated
samples show several cell divisions indicative of active
proliferation, whereas the PBS sample did not (Figure 5A,
left). Although all treated DCs promoted a 7-day proliferation
in more than 75% of CD4+ cells (Figure 5A, right), their
proliferation indices show an additive effect for DBF and
dmLT (Figure 5A, left); which is suggestive of an antigen
dosage-independent effect.
The frequencies of CD4+ cells secreting Th1 cytokine
IFN-γ and Th17 cytokine IL-17A were analyzed by ELISpot
and compared across groups. CD4+ cells cultured with
unstimulated DCs are exclusively IFN-γ secreting cells.
Conversely, the frequency of cells distributes heavily toward
IL-17A secreting cells when DBF, dmLT or the combination
is used. We observed an overall reduction in the amount of
secreting cells (irrespective of cytokine) in the dmLT only
sample. Interestingly, a small population of dual-secreting
cells was found in samples with dmLT with or without
DBF (Figure 5B).
The amount of cytokines secreted in the supernatant by
these co-cultures was then measured in a multiplex assay.
The pattern of IFN-γ vs. IL-17A secretion observed in the
ELISpot assays was confirmed in co-cultures of T cells with
unstimulated vs. DBF+dmLT stimulated DCs, and levels are
markedly different even when treatment groups are compared
for each cytokine (Figure 5C). IFN-γ is mostly present in
T cells cultured with unstimulated DCs. Similarly, IL-2
is significantly higher in samples with unstimulated DCs
(Figure 5C, left panels) whereas samples with DBF+dmLT
stimulated DCs, in addition to high secretion of IL-17A, had
significantly higher levels of Th17 cytokines IL-17F and IL-22
(Figure 5C, right panels).
DCs Stimulated With DBF +dmLT Protect
Mice in a S. flexneri Challenge
We determined the potential of DCs to generate protective
responses by intranasal adoptive transfer of DCs unstimulated
or stimulated with DBF+dmLT. We decided not to transfer
cells treated with DBF without adjuvant as we previously
FIGURE 4 | Cytokine secretion by DC after various treatments. DC
populations exposed to PBS, DBF, dmLT, and the combination DBF+dmLT
show different patterns of cytokine secretion and are presented according to
their T-cell polarization role. A. IL-6, a cytokine critical for Th17 lineage
commitment is enriched in all antigen-treated populations 2 h post-treatment.
All samples are significantly different than PBS. (B) Th1-polarizing cytokine
IL-12p70 is not significantly different across treatments. (C) Th2-polarizing
cytokine IL-4 was significantly different in all antigen-treated samples vs. PBS.
(D) IL-10 had an incremental secretion pattern, with all antigen-treated
samples significantly different than the PBS control, and significant differences
between DBF and dmLT or DBF+dmLT. Each bar represents the mean and
SD of duplicate biological samples. Statistical significance was analyzed with
an ordinary one-way ANOVA with a Tukey post-hoc test. All comparisons
tested with an α value of 0.05. *p < 0.05, **p < 0.01.
demonstrated that DBF by itself is not able to provide protection
in mice (10). These cells were transferred three times 14 days
apart to 15 mice. Additionally, various vaccination groups were
probed for protective efficacy in a lethal pulmonary challenge
with wild-type S. flexneri (Figure 6A) after 56 days of the first
immunization. After the challenge, the control group receiving
DBF+dmLT formulation intranasally showed 100% protection.
As expected, most of the PBS immunized mice succumbed to
S. flexneri challenge, showing only 10% survival. While the
unstimulated DCs did not provide any protection against S.
flexneri, the DCs stimulated with DBF +dmLT provided a 50%
protection against challenge (Figure 6B). This difference was
significantly different from the DC media transferred group and
PBS negative controls. We analyzed the immune responses in
these mice in order to characterize the responses generated by the
antigen stimulated dendritic cells. We analyzed the frequencies
of antibody secreting cells (ASCs) specific for the delivered
antigens in the spleen and bone marrow of immunized mice via
ELISpot assays (Figure 6C). High frequencies of IgG secreting
cells were detected in mice that received the DBF and dmLT
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FIGURE 5 | Co-culture of pre-treated DCs and isolated spleen T helper cells. DC populations exposed to PBS, DBF, dmLT and the combination DBF+dmLT for 48 h
were then co-cultured for 7 days with CD4+ cells isolated from spleens of mice immunized with DBF+dmLT intranasally. (A) Proliferation of CD4+ cells was analyzed
by CFSE fluorescence patterns. Stacked histograms show the differential distributions of fluorescence intensity. Numbers present inside the grids indicate the
proliferation index of each population (proliferation index = average number of cell divisions during treatment). Bar graph shows the percentage of cells that
proliferated after day 0. All antigen-treated DC co-cultures had significantly higher percentages of cell proliferation. Each bar represents the mean and SEM of
duplicate biological samples. (B) CD4+ cells were sorted post-culture and cytokine-secreting cells determined by ELISpot. IFN-γ, IL-17, or double IFN-γ+IL-17 spot
forming cells (SFC) were counted and bar graphs show the differential amounts present for each treatment. Representative well images are included, red spots are
IFN-γ SFCs and blue spots are IL-17 SFCs. Each bar represents the mean and SD of duplicate biological samples. (C) Cytokine secretion by co-cultured cells was
measured as described in methods. Each bar represents the mean and SD of duplicate biological samples. Statistical significance was analyzed with an ordinary
one-way ANOVA with a Tukey post-hoc test. All comparisons tested with an α value of 0.05. *p < 0.05.
intranasally. In contrast, the group that received DCs incubated
with DBF+dmLT did not show any detectable ASCs in these
organs. Mice that received unstimulated DCs or PBS intranasally
did not show detectable ASCs specific for IpaB. The lack of ASCs
in the DC transferred mice was confirmed by measuring IgG in
serum using ELISA (not shown). In order to characterize the T
cell responses in these mice we performed dual color ELISpots
to measure IFN-γ and IL-17A secreting cells specific for IpaB,
IpaD and dmLT. Splenocytes obtained from mice that received
unstimulated DCs showed no antigen specific cytokine-secreting
cells. Frequencies for IFN-γ- and IL-17A-secreting cells specific
for IpaB are similar in splenocytes from mice that received
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FIGURE 6 | Adoptive transfer of DCs. (A) Immunization layout employed for transfer experiments. (B) Dendritic cells stimulated with PBS, or the combination
DBF+dmLT for 48 h were administered intranasally to mice. Mice (N = 10) were challenged with 2 × 107 CFU of Shigella flexneri 2457T. Animals immunized three
times intranasally with DBF+dmLT or PBS were used as positive and negative controls, respectively. Survival was monitored for 14 days. **p < 0.01 compared to
survival of mice vaccinated with PBS using log-rank Mantel-Cox test, n.s. not significant. (C) Splenocytes and bone marrow cells from mice that were transferred DCs
or vaccinated with protein were used in an ELISpot measuring IgG secreting cells specific for the DBF chimeric portion IpaB. (D) Splenocytes were stimulated with
IpaB, IpaD or dmLT for 48 h. cytokine-secreting cells were determined by ELISpot. IFN-γ and IL-17A spot forming cells (SFC) were counted and bar graphs show the
differential amounts present for each treatment. Each bar represents the mean and SD of biological replicates (five individuals/group). Statistical significance was
analyzed with a 2-way ANOVA with a Sidak post-hoc test. All comparisons tested with an α value of 0.05. *p < 0.05 in the frequencies of IFN-γ secreting cells.
proteins intranasally or that received DCs incubated with DBF
+dmLT (Figure 6D). The same samples stimulated with IpaD or
dmLT have significantly more IFN- γ secreting cells in the mice
that received DCs incubated with DBF +dmLT. The frequencies
in IL-17A secreting cells specific for IpaD or dmLT were similar.
The negative controls in these groups did not show significant
frequencies of cytokine secreting cells.
Lack of T Cells in Vaccinated Mice
Reduces Protective Efficacy Against a
Shigella spp. Challenge
To further explore the role of cellular immunity in protection
conferred by DBF protein, we performed vaccinations on mice
lacking T cells (Tcratm1Mom) along with their control in C57BL-6
background (WT). These mice were immunized three times with
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FIGURE 7 | Immunization of T cell deficient mice. Mice (n = 15) were
immunized three times at days 0, 14, and 28 before challenge with PBS or the
combination DBF+dmLT intranasally,. Mice were challenged with 2 × 107
CFU of Shigella flexneri 2457T. Survival was monitored for 14 days. **p < 0.01
compared to survival of KO mice vaccinated with DBF +dmLT using log-rank
Mantel-Cox test.
either DBF +dmLT or PBS intranasally. At day 56, mice were
challenged with S. flexneri and survival was measured. Wild
type and mutant mice immunized with PBS did not exhibit
any differences in survival when challenged with S. flexneri.
The wild type mice that received DBF +dmLT showed a 90%
protection, while the Tcra mice had a reduction of 50% in their
survival (Figure 7).
DISCUSSION
The magnitude of the morbidity and mortality of shigellosis
in developing countries underscores the need for a safe,
effective and inexpensive vaccine. The reason for the lack
of a commercially available bradly protective Shigella vaccine
is multifactorial, contributed to by a poor understanding
of the correlates of protective immunity (15). Some studies
exist exploring the surrogates of protective immunity against
attenuated Shigella strains, but the majority of these responses
are representative of serotype-restricted immunity. Most are
primarily driven by O-antigen in the form of antibodies (6);
however, a live hybrid Shigella vaccine was found to elicit
elevated splenocyte secretion of Th1 and Th17 cytokines. Little
information exists about the surrogates of protection of subunit
vaccines against shigellosis and only descriptive data of cellular
immunity responses are available. For example, our previous
studies on DBF show an increase in IFN-γ and IL-17 secreting
cells in the spleen (10, 11), whereas IFN-γ was also found in
lung lavages of mice immunized with another subunit vaccine
based on purified OmpA (16, 17). Therefore, our study had the
goal of describing the immune responses sufficient for protection
provided by the subunit vaccine DBF when adjuvanted with
dmLT.
We have previously reported the efficacy of intranasal
immunization with a DBF+dmLT formulation against various
Shigella spp. challenges, thus, this route was used as our
experimental standard. Upon intranasal immunization, cell
populations in the NALT are responsible for antigen uptake,
cytokine secretion and transport to draining lymph nodes
(dLN) (18). Furthermore, this route has been shown to induce
Th17 stimulation, independent of adjuvant choice (19). Indeed,
mice immunized intranasally with DBF+dmLT contain antigen
presenting cell populations in the NALT that are discernibly
different from those of unimmunized animals. CD11c+ cells,
although found in similar numbers across treatments, showed
increased activation profiles in DBF+dmLT immunized animals,
as exhibited by elevated MHCII and CD86 surface expression.
Remarkably, both DBF and dmLT are needed for these
activation profiles. Although CD3+ and F4/80+ populations
are not enriched in the NALT of immunized animals, their
activation profiles in individual mice show interesting features.
Percentages of CD3+ CD69+ and F4/80+MHCII+ cells remain
homogeneous among individuals immunized with DBF or those
unimmunized but become heterogeneous upon immunization
with dmLT or DBF+dmLT. This could be due to the timing of
responses present in the NALT, as migration of macrophages
to the dLN might still be en route 6 h post-immunization. The
activation feature of the DBF protein represents an interesting
characteristic of this protein. This activity is not related to
LPS contamination as our purification scheme includes anion
exchange columns and use of a detergent for stabilization. With
these procedures, the total levels of endotoxin are consistently
under 0.1 E.U. More probably, this activity can be related to the
intrinsic activity of IpaB and IpaD, which are able to activate
macrophages (20, 21).
DC response to antigen treatment was elevated when a
simplified in vitro model was used. Antigen-treated CD11c+
populations are, as in the NALT, positive to MHCII and CD86.
However, the appearance of a third population with higher
expression of these markers (i.e., trimodal distributions) indicate
the population is being drawn toward a highly activated state.
Furthermore, CD80 is now differentially expressed by dmLT
and DBF+dmLT treated DCs and this is preferentially seen for
dmLT in populations with a moderate level of CD86 (CD86lo).
Kinetics of CD80 and CD86 expression in DCs have been
shown to influence the phenotype of their primed T cells,
primarily inmarkers of antigen responsiveness. A CD86 response
preferentially induces sustained T cell activation and a CD80
response promotes inhibitory signaling due to its increased
affinity to CTLA-4 (22). Thus, the occurrence of elevated CD80
responses in dmLT-treated samples in our in vitro system might
be counterproductive to T cell stimulation. The differences
between our in vivo and in vitro experiments could be related
to a difference in concentration reached in tissues vs. the ones
used in culture. Another difference is the presence of distinct
DC populations in resident tissue that respond to these proteins,
whereas a single homogeneous DC population is used for our
in vitro experiments.
In vaccine studies, the stimulation of Th populations that
respond in a manner similar to a natural infection is desirable.
Previous studies with transgenic mice have shown that IFN-γ-
secreting T and NK cells are necessary for bacterial clearance
during a Shigella infection, and ultimately, for survival (23, 24).
Newer evidence points to the role of IL-17A in reducing the
bacterial load upon reinfection, which induces a 6:1 balance
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of Th17 and Th1 populations at the site (13). Our results
show antigen treatment of DCs induces a primarily Th17-
promoting environment via increased IL-6, as confirmed by
CD4+ populations that secrete IL-17A, IL-17F, and IL-22. Also,
DC treatment could restrict Th1 differentiation and T cell
activation due to the effects of IL-10 (25). In contrast, untreated
DCs showed in vitro a Th1 polarization bias, evidenced by the
marked reduction in Th17 responses.
Our challenge data supports the idea that activated DCs,
obtained by culture with the antigens present in our vaccine
formulation DBF and dmLT are able to protect against Shigella
infection albeit at a lower extent than intranasal immunization
does. T cells that are generated in vivo after transfer of antigen-
primed DCs mainly show secretion of IFN- γ or IL-17A in levels
comparable to the protein based immunization. The difference
in protection suggests that other responses are required for
the levels of protection observed with the proteins. The lack
of humoral responses to IpaB and IpaD would suggest that
both cellular and humoral responses are required in tandem to
generate the most efficient protection in this vaccine. The site of
DC transfer also plays a role in the outcome of the vaccinations,
as experiments where DCs were transferred via intraperitoneal
injection failed to provide protection (data not shown).
These conclusions are supported by the incomplete reduction
of protection observed in the Tcra KO mice. Humoral responses
in these mice could provide partial protection in the absence
of T cell mediated responses. It is relevant then to probe the
mechanism of antibody-mediated protection in this vaccine.
In conclusion, the DBF protein is able to activate DCs in
conjunction with the adjuvant dmLT in a way that promotes
polarization of T cells to a Th1 or Th17 profile. We also
provide evidence that intranasal transfer of activated DCs
generate DBF specific T cells that allow mice to survive a
lethal Shigella challenge (50% survival rate), with a reduced
efficacy probably due to a lack of humoral responses. Therefore,




Antibodies were from Tonbo Biosciences, Biolegend or
BD Biosciences. 5-(and−6)-Carboxyfluorescein diacetate
succinimidyl ester (CFSE) was from Tonbo Biosciences (San
Diego, CA). EasySep PE selection kit was from STEMCELL
(Vancouver, Canada). Purification columns HisTrap Crude FF
and HiTrap Q FF were from GE Healthcare (Piscataway, NJ).
U-PLEX kits were from Meso Scale Discovery (Rockville, MD).
Double-color ELISPOT kits were from Cellular Technology
Limited (Cleveland, OH). N,N-Dimethyldodecylamine N-oxide
(LDAO) solution was from Sigma-Aldrich (St. Louis, MO).
Limulus Amebocyte Lysate (LAL) endpoint chromogenic kit was
from Lonza (Allendale, NJ). All cell culture plastics were TPP
brand from MidSci. Recombinant premium-grade GM-CSF was
from Miltenyi Biotec (San Diego, CA). RPMI-1640 and fetal
bovine serum were fromMediatech (Manassas, VA).
Protein Purification
Recombinant protein expression was carried out as previously
described (10). Briefly, E. coli Tuner DE3 cells were transformed
with DBF/pET28a, grown in culture, and expression induced.
The purification scheme included IMAC and anion-exchange
chromatography. Protein was tested for presence of LPS by
Limulus Amebocyte Lysate (LAL) assay and determined to be
LPS free (<0.1 EU/ml). All proteins were stored at −80◦C
until use. Adjuvant dmLT was provided by John Clements at
Tulane University.
Animal Use Statement
Animals were housed and handled in agreement with University
of Kansas’ Institutional Animal Care and Use Committee
practices (protocol AUS 221-01).
Mice IN Immunizations
Female BALB/c Mice (6–8 weeks old) or C57BL/6J and
B6.129S2-Tcratm1Mom/J (Tcra) from Jackson Laboratory were
anesthetized using isoflurane delivered via a vaporizer and
immunized intranasally (20 µl volume) three times in 2-week
intervals with 20 µg of DBF with 2.5 µg of dmLT in sterile PBS.
Challenge
Mice (10/15 per group) were anesthetized with isoflurane and
then challenged intranasally with 2× 107 CFU of S. flexneri in 20
µl. Animals were monitored for weight loss and health score for
14 days. Mice that lost more than 20% of their starting weight for
more than 48 h or remained too sick were humanely euthanized.
These experiments were performed twice with similar results.
Cell Staining and Flow Cytometry
Antibodies used were anti-CD80 PerCP-Cy5.5 Clone 16-10A1
and anti-CD86 PE Clone GL-1 from BD Biosciences; anti-
CD40 FITC Clone 3/23 from Biolegend; and anti-CD11c APC-
Cy7 Clone N418, anti-MHCII APC Clone M5/114.15.2, anti-
F4/80 PE Clone BM8.1, anti-CD69 FITC Clone H1.2F3, anti-
CD3 VioletFluor450 Clone 17A2, anti-MHCII FITC Clone
M5/114.15.2, anti-CD4 PE Clone GK1.5, and anti-CD16/CD32
Clone 2.4G2 (Fc-block) from Tonbo Biosciences. Isolated cells
were stained following a basic protocol based on a method
previously described (26). Briefly, cells were washed with 2%
BSA in PBS and incubated with Fc-block reagent for 10min
on ice. Then, cells were incubated with appropriate antibodies
for 30min and washed twice with 2% BSA in PBS. All
cell suspensions were analyzed with a BD FACSAria Fusion.
Fluorescence minus one (FMO) samples were used to set the
gates for each marker. Data analysis of flow cytometry data was
performed with FlowJo (Ashland, OR) or FCS Express (Glendale,
CA) software.
Dendritic Cell Isolation
Femurs of female BALB/c mice were used for bone marrow
isolation and differentiation into CD11c+ cells based on a
method previously described (27). Briefly, bone marrow cells
washed with cold media were treated with red cell lysis buffer and
strained with a nylonmesh. A single cell suspension was grown in
the presence of GM-CSF (20 ng/ml) for 8 days. On day 3, floating
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cells were gently removed. On day 8, adherent macrophages and
dendritic cell in suspension were evident; only suspension cells
were recovered. These cells were determined to be immature
dendritic cells by staining with an anti-CD11c antibody. Cell
populations were consistently >95% CD11c positive.
Dendritic Cell Stimulation
1 × 106 immature dendritic cells were seeded onto 60mm
tissue culture dishes in RPMI-1640 medium containing 10% FBS
and penicillin/streptomycin and stimulated as described before
(26). Briefly, cells were incubated for 48 h with recombinant
proteins at a concentration of 10µg/ml. After stimulation,
cells were harvested and stained for cell surface markers. Cell
supernatant was collected and frozen at −20◦C for cytokine
secretion analysis.
T Cell Co-culture
CD4+ memory T cells were isolated from spleens of BALB/c
mice previously immunized intranasally with DBF+dmLT (day
56 after first immunization) as previously described (14, 26, 28).
A single cell suspension was stained with a PE anti-mouse
CD4 antibody as described above. Then, cells were incubated
in a solution 2% FBS 1mM EDTA in PBS with a PE selection
cocktail. CD4+ cells were isolated by positive selection with
magnetic particles, washed and resuspended in PBS. These
cells were then stained with a 5-(and−6)-Carboxyfluorescein
diacetate succinimidyl ester (CFSE) solution for proliferation
studies. 1 × 106 stimulated dendritic cells and 5 × 105 T
helper cells were then co-incubated in a 24-well plate with
media for 7 days. CD4+ cells were analyzed for CFSE labeling
after co-culture and sorted for ELISpot assays with a BD
FACSAria Fusion.
Dendritic Cell Immunizations
Mice were anestethized using isoflurane. Cultured dendritic cells
were administered intranasally at days 0, 14, and 28 of the study
(based on 24, 26). Briefly, antigen-stimulated dendritic cells were
harvested and washed three times with sterile PBS. 1 × 106 cells
in 30 µl of PBS were applied to nares of anesthetized mice.
NALT Isolation
Mice were euthanized and NALT tissue was extracted from
the upper mouth cavity from individual mice (N = 5 per
treatment/time point) under aseptic conditions and stored
in complete RPMI. A single cell suspension was obtained
by homogenization through a nylon mesh and washed
with cold media. Staining for surface markers was done as
described above.
Cytokine Determinations
Supernatants collected from dendritic cell stimulations or
co-cultures were analyzed with U-PLEX kits for cytokines IL-
4, IL-6, IL-10, and IL-12p70; and IFN-γ, IL-2, IL-17A, IL-
17F, and IL-22, respectively. Cytokine concentrations were
determined with a MSD plate reader and associated software
(Meso Scale Discovery).
ELISpot
Sorted CD4+ cells from co-cultures were plated onto ELISpot
plates coated with antibodies against IFN-γ and IL-17A for a
dual-color assay. Cytokine-secreting cells were analyzed with
a CTL immunospot reader (Cellular Technology Limited).
Splenocytes from mice transferred dendritic cells were collected
and restimulated with IpaB, IpaD, or dmLT for 48 h. These cells
were then plated in ELISpot dual-color assay plates and assayed
as described.
Statistical Analysis
All graphs and statistical comparisons were done with
GraphPad Prism (version 6 or 7). The data is represented
as mean with SD or mean with SEM (when individual values
were plotted). Representative data from one experiment
is presented, in vitro experiments were performed at
least 3 times and in vivo experiments performed twice.
Appropriate tests were used for statistical analysis,
including one-way and two-way ANOVA, and log-rank
Mantel-Cox test. A p < 0.05 was considered significant in
all comparisons.
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